Information Provided By: 
Fly News Breaks for January 29, 2016
CELG
Jan 29, 2016 | 08:06 EDT
UBS said there is no change to their bullish stance on Celgene as the company's Q4 report continued to show high quality earnings with a majority of product sales growth driven by volume. The firm sees continued geographic expansion and sees Celgene as having the strongest model among mega-cap biotech companies. UBS reiterated its Buy rating and $145 price target on Celgene shares.
News For CELG From the Last 2 Days
There are no results for your query CELG
